

SN	CTA#	Title	Principal Investigator	Applicant
1	0001	Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-center, parallel-group, two arm randomized placebo controlled superiority trial	Dr. Robert Opika Opoka	Department of Pediatrics and Child Health, Makerere University College of Health Sciences
2	0002	Doxycycline for the treatment of nodding syndrome: A phase II, randomised placebo controlled trial	Dr. Richard Idro	Department of Pediatrics and Child Health, Makerere University College of Health Sciences
3	0003	Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability, and Anti-Retroviral Activity of GSK 1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents	Dr. Linda Barlow Mosha	MU-JHU Care Ltd.
4	0004	Prevention of Malaria in HIV-uninfected Pregnant Women and Infants (PROMISE Birth Cohort 3)	Prof .Moses Kanya	MU-UCSF
5	0005	A Phase 3, Randomized , Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS -9883/ Emtricitabine/Tenofovir Alafenamide (GS - 9883/F/TAF) from Elvitegravir /Cobicistat /Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF), or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women	Dr. Cissy Kityo Mutuluza	Joint Clinical Research Centre
6	0006	A randomized trial of dolutegravir (DTG)-based antiretroviral therapy vs standard of care (SOC) in children with HIV infection starting first line or switching to second line ART.	DR .Cissy Kityo Mutuluza	Joint Clinical Research Centre

***This data is limited to the trials received in 2016***

7	0007	Pharmacokinetics of efavirenz 400 mg once daily during pregnancy in HIV -1 infected women.	Dr. Mohammed Lamorde	Infectious Disease Institute
8	0008	<b>IN</b> vestigation of rheumati <b>C</b> AF Treatment <b>U</b> sing vitamin K antagonists, rivaroxaban or aspirin <b>S</b> tudies. (INVICTUS)	Dr. Emmy Okello	Uganda Heart Institute
9	0009	A Multi-center, Phase 3B Open-label Follow-up trial to assess the continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women.	Dr. Brenda Gati Mirembe	MUJHU care Ltd.
10	0010	A Multi-country, prospective, clinical safety study of subjects exposed to the candidate Ebola vaccines Ad26.ZEBOV and/or MVA –BN-Filo	Prof. Pontiano Kaleebu	MRC/UVRI
11	0011	A Pharmacokinetic Evaluation of Increased Dose Levonogestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIVInfected Women	Dr. Mohammed Lamorde	Infectious Diseases Institute
12	0012	A multicenter, open label , randomized , multiple dose , two period crossover, bioequivalence study of Liposomal Amphotericin B injection (Cipla Ltd. , India) and Ambisome® Liposome for injection (Gilead life sciences, USA ) in adult patients with fungal infections	Dr. Henry Mugerwa	Joint Clinical Research Centre
13	0013	A Follow-Up Open Label Trial to Assess The Continued Safety of and Adherence to the Dapivirine (25mg) Vaginal Ring-004 in Healthy HIV-Negative Women (Phase IIIb)	Dr. Sylvia Kusemererwa	MRC/UVRI
14	0014	Strategy for Maintenance of HIV Suppression with Elvitegravir + Darunavir +Ritonavir in Children (SMILE PROTOCOL)	Dr. Victor Musime	Joint Clinical Research Centre
15	0015	Defining the Molecular profile of Breast Cancer in Uganda and its Clinical Implications	Dr. Jackson Orem	Uganda Cancer Institute
16	0016	Optimizing Hydroxyurea Therapy in Children with Sickle Cell Anemia in Malaria Endemic Areas : The NOHARM Maximum Tolerated Dose (MTD) Extension Study	Dr. Robert Opika Opoka	Global Health Uganda / PEDIATRIC DEPT. Mulago Hospital

*This data is limited to the trials received in 2016*

17	0017	The effect of modified F-75 on diarrhea in the treatment of children with severe acute malnutrition.	Dr. Elizabeth Kiboneka	Mwana Mugimu Nutrition Unit, Mulago Hospital
18	0018	A Phase 2/3 , Open Label Study of the Pharmacokinetics , Safety, and Antiviral Activity of the GS-9883/ Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) in HIV-1 infected Virologically Suppressed Adolescents and Children	Dr. Eva Natukunda	Joint Clinical Research Centre
19	0021	An open label phase I clinical trial to evaluate the effect of late boost on HIV-uninfected vaccines from EV06 trial	Prof. Pontiano Kaleebu	MRC/UVRI
20	0026	Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis among Women at High Risk for HIV infection in Kampala, Uganda	Prof. Janet Seeley	MRC/UVRI

#### Abbreviations

1. MRC/UVRI                      Medical Research Council /Uganda Virus Research Institute
2. MU-UCSF                      Makerere University – University of California, San Francisco
3. MU-JHU                         Makerere University – John Hopkins University